Zolmitriptan Nasal Spray: A Review in Acute Migraine in Pediatric Patients 12 Years of Age or Older
Abstract The intranasal formulation of zolmitriptan, a selective serotonin 5-$ HT_{1B/1D} $ agonist, was recently approved by the US Food and Drug Administration for the treatment of acute migraine in pediatric patients 12 years of age or older. This article summarizes the efficacy and tolerability of zolmitriptan ($ Zomig^{®} $) nasal spray (NS) in acute migraine in this patient group. Zolmitriptan NS 5 mg was more effective in relieving headache pain than placebo in two double-blind studies in pediatric patients 12–17 years of age with acute migraine. Furthermore, zolmitriptan NS 2.5 and 5 mg effectively relieved photophobia and phonophobia, and was associated with a faster return to normal daily activities than placebo. Zolmitriptan NS is rapidly absorbed from the nasal mucosa and is associated with a fast onset of action, with one study showing a significant difference versus placebo with regard to headache response 15 min after administration. In both trials, zolmitriptan NS was generally well tolerated, with no serious adverse events. In conclusion, zolmitriptan NS provides rapid, effective and generally well tolerated treatment of acute migraine in pediatric patients 12 years of age or older and may be of particular benefit for those with nausea or not easily able to swallow tablets..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2016 |
|---|---|
| Erschienen: |
2016 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:18 |
|---|---|
| Enthalten in: |
Pediatric drugs - 18(2016), 1 vom: 08. Jan., Seite 75-81 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
McKeage, Kate [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
|---|
| doi: |
10.1007/s40272-015-0160-2 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR033314772 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR033314772 | ||
| 003 | DE-627 | ||
| 005 | 20230519200549.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201007s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s40272-015-0160-2 |2 doi | |
| 035 | |a (DE-627)SPR033314772 | ||
| 035 | |a (SPR)s40272-015-0160-2-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q ASE |
| 100 | 1 | |a McKeage, Kate |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Zolmitriptan Nasal Spray: A Review in Acute Migraine in Pediatric Patients 12 Years of Age or Older |
| 264 | 1 | |c 2016 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract The intranasal formulation of zolmitriptan, a selective serotonin 5-$ HT_{1B/1D} $ agonist, was recently approved by the US Food and Drug Administration for the treatment of acute migraine in pediatric patients 12 years of age or older. This article summarizes the efficacy and tolerability of zolmitriptan ($ Zomig^{®} $) nasal spray (NS) in acute migraine in this patient group. Zolmitriptan NS 5 mg was more effective in relieving headache pain than placebo in two double-blind studies in pediatric patients 12–17 years of age with acute migraine. Furthermore, zolmitriptan NS 2.5 and 5 mg effectively relieved photophobia and phonophobia, and was associated with a faster return to normal daily activities than placebo. Zolmitriptan NS is rapidly absorbed from the nasal mucosa and is associated with a fast onset of action, with one study showing a significant difference versus placebo with regard to headache response 15 min after administration. In both trials, zolmitriptan NS was generally well tolerated, with no serious adverse events. In conclusion, zolmitriptan NS provides rapid, effective and generally well tolerated treatment of acute migraine in pediatric patients 12 years of age or older and may be of particular benefit for those with nausea or not easily able to swallow tablets. | ||
| 650 | 4 | |a Migraine |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Sumatriptan |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Migraine Attack |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Nasal Spray |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Zolmitriptan |7 (dpeaa)DE-He213 | |
| 773 | 0 | 8 | |i Enthalten in |t Pediatric drugs |d Berlin [u.a.] : Springer, 1999 |g 18(2016), 1 vom: 08. Jan., Seite 75-81 |w (DE-627)SPR033305722 |w (DE-600)2043681-6 |x 1179-2019 |7 nnns |
| 773 | 1 | 8 | |g volume:18 |g year:2016 |g number:1 |g day:08 |g month:01 |g pages:75-81 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s40272-015-0160-2 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OPC-PHA | ||
| 912 | |a SSG-OPC-ASE | ||
| 951 | |a AR | ||
| 952 | |d 18 |j 2016 |e 1 |b 08 |c 01 |h 75-81 | ||